Cingulate (CING) Q1 2026 earnings summary

Executive summary

• Focused on developing once-daily, multi-dose therapies for ADHD and anxiety using proprietary drug delivery technology; lead candidate CTx-1301 is in late-stage development with NDA submitted and FDA review ongoing, targeting a PDUFA date of May 31, 2026.

• No product approvals or revenue to date; operations funded by equity and debt, with $151.9 million raised since inception.

• Commercial launch preparations include AI-driven tools, expanded sales force, and manufacturing scale-up.

• Net loss for Q1 2026 was $9.3 million, up from $3.9 million in Q1 2025, driven by increased pre-commercialization and regulatory activities.

Financial highlights

• Cash and cash equivalents at March 31, 2026 were $25.9 million, up from $10.95 million at December 31, 2025, mainly from a $12 million private placement.

• Working capital increased to $17.0 million from $1.7 million at year-end 2025.

• General and administrative expenses rose to $5.7 million (up 287% year-over-year), mainly due to commercialization readiness for CTx-1301.

• Research and development expenses were $2.2 million, down 1.8% year-over-year as clinical operations wound down.

• Net loss for Q1 2026 was $9.3 million, up from $3.9 million in Q1 2025, mainly due to higher G&A and changes in derivative fair value.

Outlook and guidance

• Cash runway expected to fund operations into early 2027, including regulatory and commercial launch costs for CTx-1301 if approved.

• Additional capital will be needed to advance other programs and support long-term growth.

• Ongoing efforts to secure funding through equity, debt, or strategic transactions.

• Commercial launch of CTx-1301 contingent on FDA approval, with infrastructure and field force ready for deployment.